Von E confirmation reheats
This article was originally published in The Tan Sheet
Senate Finance chair Chuck Grassley (R-Iowa) places a hold on the nomination of Andrew von Eschenbach's nomination for FDA Commissioner Nov. 17. Grassley objects to the acting commissioner's failure to comply with subpoenas the committee issued in May for FDA documents related to Sanofi-Aventis' antibiotic Ketek. "The authority and integrity of Senate and Committee processes are being challenged," says Grassley. A day earlier, during a hearing on drug safety, Senate Health Committee Chairman Michael Enzi (R-Wyo.) urged colleagues to take up a vote on the nominee. "Give Dr. von Eschenbach the chance to effectively run the FDA with full statutory authority," Enzi said. Holds from Sen. David Vitter (R-La.) and Sen. Jim DeMint (R-S.C.) also remain in place. After the hearing, Enzi told reporters he continues working to lift those holds. If action is not taken during the lame duck session, incoming chair Edward Kennedy (D-Mass.), who supports the nomination, appears likely to continue to press for confirmation...
You may also be interested in...
Continued criticism of FDA Acting Commissioner Andrew von Eschenbach by Senate Finance Committee Chairman Charles Grassley (R-Iowa) suggests that chances of a Senate vote on the nominee as full commissioner during Congress' lame-duck session have not brightened
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Viatris has weighed in on the FTC’s continued investigations into US healthcare middlemen, arguing that it can be a good thing for an industry battling shortages, even as the firm continues to rationalize products that do not make sense economically.